Bio-Techne Overview
- Year Founded
-
1976
- Status
-
Public
- Employees
-
3,000
- Stock Symbol
-
TECH
- Investments
-
34
- Share Price
-
$72.71
- (As of Thursday Closing)
Bio-Techne General Information
Description
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Contact Information
Website
www.bio-techne.comCorporate Office
- 614 McKinley Place North East
- Minneapolis, MN 55413
- United States
Corporate Office
- 614 McKinley Place North East
- Minneapolis, MN 55413
- United States
Bio-Techne Stock Performance
As of 19-Nov-2026, Bio-Techne’s stock price is $72.71. Its current market cap is $11.4B with 157M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $72.71 | $72.75 | $43.20 - $72.88 | $11.4B | 157M | 2.91M | $1.10 |
Bio-Techne Financials Summary
As of 30-Sep-2026, Bio-Techne has a trailing 12-month revenue of $1.23B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 11,388,993 | 11,088,526 | 8,348,506 | 11,640,357 |
| Revenue | 1,228,196 | 1,215,039 | 1,219,635 | 1,159,060 |
| EBITDA | 327,786 | 343,446 | 212,989 | 309,813 |
| Net Income | 171,970 | 181,862 | 73,400 | 168,105 |
| Total Assets | 2,636,820 | 2,586,726 | 2,557,868 | 2,703,867 |
| Total Debt | 285,555 | 289,087 | 444,058 | 419,538 |
Bio-Techne Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bio-Techne Comparisons
Industry
Financing
Details
Bio-Techne Competitors (19)
One of Bio-Techne’s 19 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| Meridian Bioscience | Private Equity-Backed | Cincinnati, OH | ||||
| Thermo Fisher Scientific | Formerly PE-Backed | Waltham, MA | ||||
| Revvity | Corporation | Waltham, MA | ||||
| BioMérieux | Formerly PE-Backed | Marcy-l'Etoile, France |
Bio-Techne Patents
Bio-Techne Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231614-A1 | Engineered fgf4 polypeptides, compositions, and uses thereof | Pending | 28-Apr-2025 | ||
| WO-2026178548-A1 | Engineered fgf10 polypeptides, compositions, and uses thereof | Pending | 24-Feb-2025 | ||
| WO-2026151761-A1 | Engineered il-15 polypeptides, compositions, and uses thereof | Pending | 07-Jan-2025 | ||
| WO-2026076112-A1 | Variants of activin a | Pending | 01-Oct-2024 | ||
| WO-2026029980-A1 | True spectral flow cytometers | Pending | 15-Jul-2024 | G01N15/1434 |
Bio-Techne Signals
Bio-Techne Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bio-Techne Investments & Acquisitions (34)
Bio-Techne’s most recent deal was a Early Stage VC with Spear Bio for . The deal was made on 23-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Spear Bio | 23-Jul-2024 | Early Stage VC | Other Healthcare Technology Systems | ||
| Lunaphore | 07-Jul-2023 | Merger/Acquisition | Diagnostic Equipment | ||
| Wilson Wolf Manufacturing | 31-Mar-2023 | Corporate | Diagnostic Equipment | ||
| Namocell | 30-Jun-2022 | Merger/Acquisition | Biotechnology | ||
| Asuragen | 06-Apr-2021 | Merger/Acquisition | Diagnostic Equipment |
Bio-Techne ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
26.49 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Bio-Techne Exits (7)
Bio-Techne’s most recent exit was on 01-Aug-2018 from Exosome Diagnostics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Exosome Diagnostics | 01-Aug-2018 | Completed |
|
||
| Astute Medical | 14-Dec-2016 | Completed |
|
||
| Chemocentryx | 08-Feb-2012 | Completed |
|
||
| Chemocentryx | 08-Mar-2007 | Completed |
|
||
| Chemocentryx | 18-Jun-2004 | Later Stage VC | Completed |
|
Bio-Techne Affiliates
Subsidiaries (9)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Lunaphore | Tolochenaz, Switzerland | 2014 | |
| Advanced Cell Diagnostics | Minneapolis, MN | 2006 | |
| Shanghai PrimeGene Bio-Tech Company | Shanghai, China | 2006 | |
| Asuragen | Austin, TX | 2005 | |
| Eurocell Diagnostics | Rennes, France | 2003 |
Bio-Techne FAQs
-
When was Bio-Techne founded?
Bio-Techne was founded in 1976.
-
Where is Bio-Techne headquartered?
Bio-Techne is headquartered in Minneapolis, MN.
-
What is the size of Bio-Techne?
Bio-Techne has 3,000 total employees.
-
What industry is Bio-Techne in?
Bio-Techne’s primary industry is Discovery Tools (Healthcare).
-
Is Bio-Techne a private or public company?
Bio-Techne is a Public company.
-
What is Bio-Techne’s stock symbol?
The ticker symbol for Bio-Techne is TECH.
-
What is the current stock price of Bio-Techne?
As of 19-Nov-2026 the stock price of Bio-Techne is $72.71.
-
What is the current market cap of Bio-Techne?
The current market capitalization of Bio-Techne is $11.4B.
-
What is Bio-Techne’s current revenue?
The trailing twelve month revenue for Bio-Techne is $1.23B.
-
Who are Bio-Techne’s competitors?
Bio-Rad Laboratories, Meridian Bioscience, Thermo Fisher Scientific, Revvity, and BioMérieux are some of the 19 competitors of Bio-Techne.
-
What is Bio-Techne’s annual earnings per share (EPS)?
Bio-Techne’s EPS for 12 months was $1.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process